Enliven Therapeutics, Inc. (ELVN) vs Pulse Biosciences, Inc. (PLSE)

A side-by-side comparison of Enliven Therapeutics, Inc. and Pulse Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ELVN vs PLSE

growth of $100 · dividends reinvested · last 7y
ELVN -24.2% (-3.9%/yr)PLSE +730.6% (+35.3%/yr)PLSE compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$76$831
ELVN PLSE

ELVN vs PLSE: by the numbers

  • •PLSE is the larger company ($3.44B vs $3.06B market cap).
  • •Both run net losses; ELVN's is the smaller (0.00% vs -6755.78% net margin).

Metrics side by side

Valuation

MetricELVNPLSE
P/S ratioN/A2900.97
P/B ratio3.4234.55

Profitability

MetricELVNPLSE
Gross margin0.00%-360.00%
Operating margin0.00%-21982.57%
Net margin0.00%-6755.78%
ROE-11.83%-80.46%
ROIC-13.88%-79.40%

Growth (annualized)

MetricELVNPLSE
Total return CAGR (5Y)24.57%19.76%

Frequently asked

How have ELVN and PLSE total returns compared?
Over the past 5 years, ELVN delivered 24.57% and PLSE delivered 19.76% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.